Hcw Biologics Stock Debt To Equity
| HCWB Stock | USD 0.32 0.04 11.11% |
HCW Biologics fundamentals help investors to digest information that contributes to HCW Biologics' financial success or failures. It also enables traders to predict the movement of HCW Stock. The fundamental analysis module provides a way to measure HCW Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HCW Biologics stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.48 | 0.50 |
HCW | Debt To Equity |
HCW Biologics Company Debt To Equity Analysis
HCW Biologics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current HCW Biologics Debt To Equity | 0.01 % |
Most of HCW Biologics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HCW Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
HCW Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for HCW Biologics is extremely important. It helps to project a fair market value of HCW Stock properly, considering its historical fundamentals such as Debt To Equity. Since HCW Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of HCW Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of HCW Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
HCW Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, HCW Biologics has a Debt To Equity of 0.005%. This is 99.99% lower than that of the Biotechnology sector and 99.97% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.99% higher than that of the company.
HCW Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HCW Biologics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HCW Biologics could also be used in its relative valuation, which is a method of valuing HCW Biologics by comparing valuation metrics of similar companies.HCW Biologics is currently under evaluation in debt to equity category among its peers.
HCW Fundamentals
| Return On Equity | -3.44 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (22.36) % | ||||
| Current Valuation | 22.49 M | ||||
| Shares Outstanding | 37.82 M | ||||
| Shares Owned By Insiders | 52.30 % | ||||
| Shares Owned By Institutions | 3.10 % | ||||
| Number Of Shares Shorted | 8.09 K | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 3.47 X | ||||
| Revenue | 2.84 M | ||||
| Gross Profit | 4.1 M | ||||
| EBITDA | (24.58 M) | ||||
| Net Income | (24.99 M) | ||||
| Cash And Equivalents | 32.41 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 6.45 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 30.25 X | ||||
| Book Value Per Share | (0.17) X | ||||
| Cash Flow From Operations | (22.51 M) | ||||
| Short Ratio | 1.06 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 45 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 13.63 M | ||||
| Total Asset | 28.51 M | ||||
| Retained Earnings | (70.53 M) | ||||
| Working Capital | (2.34 M) | ||||
| Net Asset | 28.51 M |
About HCW Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HCW Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HCW Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HCW Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:Check out HCW Biologics Piotroski F Score and HCW Biologics Altman Z Score analysis. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.107 | Quarterly Revenue Growth (0.01) | Return On Assets (0.70) | Return On Equity (3.44) |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.